Amarin Corporation PLC
495 articles about Amarin Corporation PLC
-
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/29/2024
Amarin Corporation plc, announced financial results for the quarter and year ended December 31, 2023 and provided an update on the Company’s operations.
-
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
2/15/2024
Amarin Corporation plc announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET.
-
Amarin Chairman & CEO Issue Letter to Shareholders - Jan 22, 2024
1/22/2024
Amarin Corporation plc announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders.
-
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
1/10/2024
Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited fourth quarter 2023 revenue and its year-end cash position, its 2023 progress and 2024 priorities and its plan to initiate a share repurchase program, ahead of its presentation to investors at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
-
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/11/2023
Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024.
-
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
11/12/2023
Amarin Corporation plc announced results from new REDUCE-IT analyses showing that among statin-treated patients in a prespecified subgroup with history of Metabolic Syndrome, but without diabetes at baseline, the addition of VASCEPA/VAZKEPA significantly reduced the risk of first and total cardiovascular events.
-
Amarin Reports Third Quarter 2023 Financial Results
11/1/2023
Amarin Corporation plc announced financial results for the quarter ended September 30, 2023 and provided an update on company operations.
-
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
10/31/2023
Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer.
-
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
10/26/2023
Amarin Corporation plc announced new supported and/or funded research from the landmark REDUCE-IT cardiovascular outcomes trial on the effects of VASCEPA®/VAZKEPA® in a specific patient subgroups at increased risk of a cardiovascular event has been accepted for presentation at the American Heart Association Scientific Sessions 2023, taking place November 11 – 13, 2023 in Philadelphia, PA.
-
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
10/19/2023
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial results on Wednesday, November 1st , 2023 at 8:00 a.m. ET.
-
Amarin to Present at the 2023 Cantor Global Healthcare Conference
9/12/2023
Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare Conference.
-
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
8/9/2023
Amarin Corporation plc announced pricing and reimbursement updates for VAZKEPA in the Netherlands and Italy.
-
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
8/8/2023
Amarin Corporation plc (NASDAQ:AMRN) and Neopharm Israel announced today that the two companies have entered into an exclusive marketing and commercialization agreement for VAZKEPA® (icosapent ethyl) in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority.
-
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
8/7/2023
The acceptance of icosapent ethyl, an innovative active substance comprising a highly purified omega-3 fatty acid (eicosapentaenoic acid greater or equal to 96%), will provide healthcare professionals in Scotland with an additional treatment option to be considered for eligible patients who are at high risk of a subsequent CV event, such as a second heart attack or stroke.
-
Amarin Reports Second Quarter 2023 Financial Results
8/2/2023
Amarin Corporation plc (NASDAQ:AMRN) today announced financial results for the quarter ended June 30, 2023 and provided an update on company operations.
-
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
7/31/2023
Amarin Corporation plc and Lotus Pharmaceuticals announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA® across 10 countries, including nine in Southeast Asia and South Korea.
-
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
7/26/2023
Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.
-
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
7/25/2023
Amarin Corporation plc (NASDAQ:AMRN) today announces that following the most recent meeting of the Spanish Drug Pricing Committee (Comisión Interministerial de Precios de los Medicamentos) on July 24, 2023, the Committee is recommending the national reimbursement of VAZKEPA® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular risk.
-
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
7/20/2023
Today the Board of Directors of Amarin Corporation plc (NASDAQ: AMRN) announced details regarding the compensation program for the Company’s new President and Chief Executive Officer (CEO), Patrick Holt, who was appointed to the role on July 18, 2023.
-
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
7/18/2023
Amarin Corporation plc announced that it has initiated an organizational restructuring program to right-size and strengthen the Company to enhance shareholder value.